How Pegloticase Plus Methotrexate is Breaking Ground in Gout Care
Last week, the US Food and Drug Administration (FDA) approved the co-treatment of pegloticase (Krystexxa) injection plus methotrexate (MTX) for uncontrolled gout, a decision bolstered by data from phase 4 of the MIRROR study.
In that study, 71% of patients who were treated with this combination therapy achieved a complete response over the course of 6 months. Comparatively, only 38.5% of patients who received pelgoticase plus placebo achieved a complete response.
In a then-recent statement, John Botson, MD, RPh, Rhuematology Director at Orthopedic Physicians Alaska stated that the medical…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.